New study tracks how leukemia drug works outside the lab
NCT ID NCT06092879
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 25 times
Summary
This study follows 201 adults with chronic myeloid leukemia who are taking the drug Scemblix (asciminib) as a third or later treatment option. The goal is to see how long patients stay on the drug and how well it works in everyday medical practice, not just in controlled trials. Researchers will track treatment patterns and molecular responses over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Angers, France, 49933, France
-
Novartis Investigative Site
Challes-les-Eaux, France, 73190, France
-
Novartis Investigative Site
Limoges, Haute Vienne, 87000, France
-
Novartis Investigative Site
Saint Priest Jarez, Pays de la Loire Region, 42270, France
-
Novartis Investigative Site
Aix-en-Provence, 13616, France
-
Novartis Investigative Site
Amiens, 80054, France
-
Novartis Investigative Site
Antibes, 06600, France
-
Novartis Investigative Site
Avignon, 84000, France
-
Novartis Investigative Site
Besançon, 25030, France
-
Novartis Investigative Site
Bobigny, 93009, France
-
Novartis Investigative Site
Bordeaux, 33000, France
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Brest, 29609, France
-
Novartis Investigative Site
Brive-la-Gaillarde, 19100, France
-
Novartis Investigative Site
Caen, 14033, France
-
Novartis Investigative Site
Cagnes-sur-Mer, 06800, France
-
Novartis Investigative Site
Cannes, 06414, France
-
Novartis Investigative Site
Castelnau-le-Lez, 34170, France
-
Novartis Investigative Site
Cesson-Sévigné, 35576, France
-
Novartis Investigative Site
Chambéry, 73000, France
-
Novartis Investigative Site
Clermont-Ferrand, 63003, France
-
Novartis Investigative Site
Corbeil-Essonnes, 91100, France
-
Novartis Investigative Site
Dunkirk, 59240, France
-
Novartis Investigative Site
Essey-lès-Nancy, 54270, France
-
Novartis Investigative Site
Grenoble, 38043, France
-
Novartis Investigative Site
Le Kremlin-Bicêtre, 94275, France
-
Novartis Investigative Site
Le Mans, 72000, France
-
Novartis Investigative Site
Lens, 62307, France
-
Novartis Investigative Site
Libourne, 33505, France
-
Novartis Investigative Site
Lorient, 56100, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Montpellier, 34070, France
-
Novartis Investigative Site
Montpellier, 34295, France
-
Novartis Investigative Site
Mulhouse, 68070, France
-
Novartis Investigative Site
Nantes, 44277, France
-
Novartis Investigative Site
Nevers, 58000, France
-
Novartis Investigative Site
Nice, 06105, France
-
Novartis Investigative Site
Nîmes, 30029, France
-
Novartis Investigative Site
Orléans, 45100, France
-
Novartis Investigative Site
Paris, 75013, France
-
Novartis Investigative Site
Paris, 75015, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Perpignan, 66046, France
-
Novartis Investigative Site
Périgueux, 24019, France
-
Novartis Investigative Site
Pierre-Bénite, 69495, France
-
Novartis Investigative Site
Poitiers, 86021, France
-
Novartis Investigative Site
Quimper, 29000, France
-
Novartis Investigative Site
Rennes, 35033, France
-
Novartis Investigative Site
Roubaix, 59100, France
-
Novartis Investigative Site
St-Malo, 35403, France
-
Novartis Investigative Site
Strasbourg, 67085, France
-
Novartis Investigative Site
Tarbes, 65100, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Tours, 37044, France
-
Novartis Investigative Site
Trévenans, 90400, France
-
Novartis Investigative Site
Troyes, 10003, France
-
Novartis Investigative Site
Valence, 26953, France
-
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54511, France
-
Novartis Investigative Site
Vesoul, 70014, France
Conditions
Explore the condition pages connected to this study.